These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 34081143)

  • 1. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
    Wang S; Sun Q; Xu Y; Pei J; Lai L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
    Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep learning model for virtual screening of novel 3C-like protease enzyme inhibitors against SARS coronavirus diseases.
    Kumari M; Subbarao N
    Comput Biol Med; 2021 May; 132():104317. PubMed ID: 33721736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2.
    Su X; Hu L; You Z; Hu P; Wang L; Zhao B
    Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34965582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
    Kumar V; Roy K
    SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking.
    Karki N; Verma N; Trozzi F; Tao P; Kraka E; Zoltowski B
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational investigation of drug bank compounds against 3C-like protease (3CL
    Joshi T; Sharma P; Mathpal S; Joshi T; Maiti P; Nand M; Pande V; Chandra S
    Mol Divers; 2022 Aug; 26(4):2243-2256. PubMed ID: 34637068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking.
    Cavasotto CN; Di Filippo JI
    Mol Inform; 2021 Jan; 40(1):e2000115. PubMed ID: 32722864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement.
    Coban MA; Morrison J; Maharjan S; Hernandez Medina DH; Li W; Zhang YS; Freeman WD; Radisky ES; Le Roch KG; Weisend CM; Ebihara H; Caulfield TR
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34071060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
    Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
    Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention Mechanism-Based Graph Neural Network Model for Effective Activity Prediction of SARS-CoV-2 Main Protease Inhibitors: Application to Drug Repurposing as Potential COVID-19 Therapy.
    Wu Y; Li K; Li M; Pu X; Guo Y
    J Chem Inf Model; 2023 Nov; 63(22):7011-7031. PubMed ID: 37960886
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Bung N; Krishnan SR; Bulusu G; Roy A
    Future Med Chem; 2021 Mar; 13(6):575-585. PubMed ID: 33590764
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
    Xiao X; Wang C; Chang D; Wang Y; Dong X; Jiao T; Zhao Z; Ren L; Dela Cruz CS; Sharma L; Lei X; Wang J
    Front Immunol; 2020; 11():586572. PubMed ID: 33324406
    [